FCPA Pharmaceutical Bribery: Congress Sponsorship and Clinical Studies That Bought Prescriptions

FCPA pharmaceutical congress sponsorship bribery ties a doctor’s funded conference attendance to the prescriptions the company wants. The same bargain can sit inside a clinical study, with payments for patient forms used to reward prescribing. If you work in sales, medical affairs or finance, you may have seen the medical purpose in one document and the sales demand in another.

Under its 2020 deferred prosecution agreement with the Justice Department, Novartis Hellas admitted using congress sponsorships for Greek public-sector ophthalmologists in exchange for increased Lucentis prescribing. Under that criminal agreement, Novartis Hellas also admitted repurposing the EXACTLY epidemiological study to increase prescriptions. Those admissions show how the invitation and the research payment could serve the same commercial objective.

When the Prescriber Holds Public Power

A doctor employed by a state hospital can be a foreign official under the Foreign Corrupt Practices Act. In pharmaceutical sales, the person making a treatment decision can also exercise public authority. That connection puts the prescriber’s employer and decision-making role alongside the payment when we examine the arrangement.

Novartis AG agreed to pay $112,800,000 under its civil settlement with the Securities and Exchange Commission. The order put the company’s unjust enrichment across the covered schemes at approximately $92.3 million.

The Commission alleged that Novartis Greece provided benefits to Greek health care providers, including employees of state-owned and state-controlled hospitals and clinics, to increase Lucentis sales. Lucentis treated wet age-related macular degeneration, among other conditions, and the subsidiary’s ophthalmology business targeted doctors it designated key opinion leaders.

These were relationships managed by people inside the sales organization. According to the order, brand and sales managers knew about and approved the misuse of educational and scientific activities, and guided subordinate staff. For an employee, that makes the manager’s instructions about a doctor’s next prescription as important as the description of the conference.

Congress Sponsorship With a Prescription Target

The Commission alleged that Novartis Greece ranked doctors by the products they prescribed, their prescribing volume and their likelihood of prescribing more Novartis drugs. Employees treated benefits as investments, planned activities around a return on that investment, and reduced or stopped support when the return fell short. Doctors were reminded of an obligation to prescribe.

Congress support supplied a benefit sales staff could offer or withdraw. The order described attendance costs that often exceeded $5,000 per doctor and internal discussions of congresses in the United States and Europe. Sales staff were told to make doctors understand that participation would be canceled unless sales performance improved significantly.

The order reproduced a manager’s action-plan message to an ophthalmology key opinion leader:

We can dispense with the educational euphemism here. The message tied the benefit to writing prescriptions, and the sponsorship could disappear when the prescriptions failed to follow. The congress invitation had become a sales incentive with an attendance badge.

The order also described demands that doctors stop using a competitor’s product and cooperate fully in return for consideration of a larger gift. Doctors considered less likely to generate sales were excluded from sponsorships and other ostensibly educational activities. We see the unfair bargain plainly: a competitor was trying to sell its medicine against a prescription tied to a gift.

For someone approving congress allocations, the telling comparison is between the medical justification and the sales team’s conditions. The purpose of the travel benefit is visible in those conditions. A real event can sit at the end of a transaction designed to purchase prescribing behavior.

FCPA Pharmaceutical Post Marketing Study Inducement

FCPA pharmaceutical post marketing study inducement uses payments for research participation to buy prescriptions. The Novartis findings show how the choice of participating doctors, the scientific rationale and the payment records can reveal that commercial purpose. They also show why medical affairs and sales can have very different explanations for the same study.

The order described Phase IV studies intended to assess a drug’s safety and efficacy, with published results to inform medical decisions. Medical Affairs was supposed to select the participating healthcare providers. In some instances, sales personnel instead selected them to promote products or induce increased prescriptions.

According to the Commission’s order, Novartis’s internal audit identified unsupported medical or scientific reasons for studies, indications of a promotional purpose, and weaknesses in collecting data and publishing results. Corporate security’s review reached similar conclusions about weak scientific rationales and the use of studies as marketing tools. The issue reached the purpose and execution of the research, well beyond whether a payment had an approval attached.

EXACTLY Paid for Forms With Thousands of Mistakes

The order linked EXACTLY to Diovan, Exforge and Rasilez. Someone who worked on a different brand may recognize the use of research payments even if the Lucentis sponsorships were outside their job.

The order reported mistakes in 25,500 of the 42,000 clinical research forms submitted in connection with EXACTLY. It also described employees’ awareness that some doctors believed they were being paid for prescriptions, and reproduced this remark from a recorded debrief:

The order described payments to some health care providers of approximately 60 euros per patient form, with some receiving as much as 38,000 euros for completing forms. It also said finance lacked visibility into study budgets and that there was no proper reconciliation between budgets and actual spending. Payments continued through a system in which the department responsible for the money could not properly compare what had been approved with what had been spent.

The participant records also diverged. According to the order, for EXACTLY approximately four times as many healthcare-provider names were submitted to the local health authority as actually received payments. Novartis Greece used dummy vendors in some instances to track study payments and budgets.

For a study coordinator or medical-affairs employee, those findings identify distinct pieces of the same problem. The submitted participant list, completed forms, payment records and sales instructions each describe a different part of what the company bought. We connect those records with your knowledge of who selected the doctors and what work they actually performed.

Advertising Expenses in the Books, Prescriptions in the Plan

The Commission alleged that Novartis Greece improperly recorded the payments as legitimate advertising and promotion or marketing and sales expenses. The subsidiary’s financial statements were consolidated into Novartis AG’s. The local description therefore traveled into the parent company’s accounting.

That is why false books and records matter alongside the corrupt exchange. The Securities and Exchange Commission’s settlement with the parent addressed alleged violations of the Foreign Corrupt Practices Act’s accounting and internal-control provisions.

For finance and accounting staff, the useful discrepancy may sit between an ordinary expense description and the commercial instruction behind it. The action plan can show that access to the benefit depended on prescriptions, while the study accounts can show who received the payment.

Fresenius Shows How the Payment Can Change Disguises

Fresenius Medical Care, a supplier of dialysis products and services, agreed to pay $147 million under its civil settlement with the Securities and Exchange Commission. The Commission alleged that employees of its Saudi distributor cashed company checks and handed the money to its general manager. According to the order, the transactions were falsely recorded as project marketing expenses and collection commissions, then consolidated into Fresenius’s books.

The same order described payments through agents in which doctors held an interest. It also alleged that an Angolan distributor owned by a military official’s sons received payment for storage services it never provided. The services varied, but the official connection and the missing work made the payment trail recognizable.

According to the order, a senior finance officer at the Saudi distributor reported false invoices and unsupported marketing and travel spending to headquarters. The Commission alleged that the conduct continued as the officer raised the concerns with the controller and internal audit. The internal warning was part of the evidence, alongside the payments themselves.

The Journal of Forensic and Investigative Accounting’s 2022 paper, Fresenius Medical Care: A Case Study on the FCPA, draws out why a written policy can leave the underlying transaction untouched:

The paper’s point is blunt: the company had policies and flagged transactions, and employees still found ways to pay bribes. In a pharmaceutical matter, the same comparison can connect a study audit or rejected sponsorship request to later approvals and spending. We want to understand who knew the commercial purpose and what happened after someone questioned it.

Whistleblower Rewards for Pharmaceutical Bribery

The Securities and Exchange Commission’s whistleblower program can pay eligible whistleblowers a combined 10% to 30% of the qualifying money collected. We assess how the FCPA whistleblower programs fit your information, including what you know about an overseas prescriber’s public role and the company’s payment records.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. That separate law concerns fraud involving government money, including claims for U.S. health care payments. We examine those connections with you and bring in whistleblower lawyers with the relevant pharmaceutical and foreign-bribery experience.

What the Sales Team and the Study Team Can Each See

The evidence connecting the decision, payment and false record can begin with the documents you already know from your work. Congress allocations show who received support. Prescriber rankings and action plans explain the sales expectation. Study forms, participant lists and payment records show who did the work and who received the money.

An insider can also explain the distance between the written purpose and the instructions people followed. You may know why a doctor’s support was renewed, why sales chose the study participants, or what finance was told when payments exceeded the available explanation. Those details give the documents their meaning, and they are the starting point for our work with you.

When You Know What the Sponsorship Bought

If you know how a congress invitation or study payment became a demand for prescriptions, speak with our whistleblower experts about the arrangement. We work beside you to build the case around the commercial decisions, identify the government connections and bring in pharmaceutical FCPA whistleblower lawyers who understand these payment channels. Talk to us about the prescribing bargain behind the paperwork so we can build your strongest pharmaceutical bribery whistleblower case.